Cargando…

Adverse events of methotrexate treatment in JIA

Detalles Bibliográficos
Autores principales:	in ‘t Veld, J, Wulffraat, NM, Swart, JF
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194562/ http://dx.doi.org/10.1186/1546-0096-9-S1-P203

Ejemplares similares

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature review
por: Van Dijkhuizen, Pieter, et al.
Publicado: (2014)

Puberty and disease activity in JIA
por: Van Pelt, Philomine, et al.
Publicado: (2014)

Use of internet in adolescents and young adults with JIA
por: Van Pelt, Philomine, et al.
Publicado: (2014)

Single-nucleotide polymorphisms in the folate pathway are associated with response to methotrexate treatment in juvenile idiopathic arthritis
por: Heijstek, MW, et al.
Publicado: (2008)

PReS-FINAL-2050: Determination of the concentration of methotrexate in the blood serum of patients with JIA
por: Rokhlina, F, et al.
Publicado: (2013)

Methotrexate shows the same efficacy and safety in the real world in all subtypes of JIA as in the controlled trial
por: Foedvari, I, et al.
Publicado: (2008)

Anaphylactic reaction to the first dose of subcutaneous methotrexate in JIA: a case report and literature review
por: Campos, Leonardo, et al.
Publicado: (2014)

Methotrexate does not primarily affect Foxp3+ regulatory T cells in poly-articular juvenile idiopathic arthritis
por: Vastert, SJ, et al.
Publicado: (2008)

IL-1 receptor antagonist restores IL-18 NK cell axis in systemic JIA
por: Vastert, Sebastiaan J, et al.
Publicado: (2012)

Investigating the use of a limited core outcome variable set for the classification of response following methotrexate treatment in juvenile idiopathic arthritis (JIA)
por: Hirani, SP, et al.
Publicado: (2008)

Evaluation of the JIA treatment with adalimumab in ukraine
por: Ponochevna, Elena, et al.
Publicado: (2014)

Investigating which variables from the core outcome variables in juvenile idiopathic arthritis (JIA) are the best predictors of classification as a responder to treatment with methotrexate (MTX)
por: Hirani, SP, et al.
Publicado: (2008)

Recombinant IL1-RA in the early phase of systemic onset JIA: before the onset of arthritis
por: Vastert, SJ, et al.
Publicado: (2011)

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, EH Pieter, et al.
Publicado: (2011)

MEFV mutations in systemic JIA
por: Aktay Ayaz, N, et al.
Publicado: (2008)

The swedish paediatric JIA-registry
por: Magnusson, Bo
Publicado: (2014)

Clinical classification of JIA in Albania
por: Vula, Aurel, et al.
Publicado: (2014)

Akinra restores the defective IL-18 NK cell axis in steroid naïve systemic onset JIA patients
por: de Jager, W, et al.
Publicado: (2011)

PReS-FINAL-2100: Methotrexate treatment affects effector, but not regulatory T cells in juvenile idiopathic arthritis
por: Vastert, S, et al.
Publicado: (2013)

Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX
por: Verkaaik, M, et al.
Publicado: (2011)

Immunomodulatory actions of methotrexate on T cells in juvenile idiopathic arthritis
por: Ćalasan, Maja Bulatović, et al.
Publicado: (2012)

The response to hepatitis a vaccine in children with JIA on immunosuppresive treatment
por: Maritsi, Despoina, et al.
Publicado: (2014)

Methotrexate restores effector T cell responsiveness in juvenile idiopathic arthritis
por: Bulatović, Maja, et al.
Publicado: (2011)

Determing an “autoimmune” phenotype in systemic JIA
por: Fischer, N, et al.
Publicado: (2011)

Effect of ANA positivity on clinical picture of the JIA: should ANA positive JIA be classified as a different group?
por: Polat, Adem, et al.
Publicado: (2011)

PReS-FINAL-2002: Adverse events during anti-TNF therapy in patients with JIA
por: Tarkiainen, M, et al.
Publicado: (2013)

Demographic, clinical and treatment characteristics of the carra registry systemic JIA cohort
por: Janow, Ginger, et al.
Publicado: (2014)

PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study
por: De Benedetti, F, et al.
Publicado: (2013)

Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
por: Joos, R, et al.
Publicado: (2011)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

Ocular threat in juvenile idiopathic arthritis (JIA)
por: Marvillet, I, et al.
Publicado: (2008)

JIA-like in a boy with Ataxia-telangiectasia
por: Furtado, Filipa, et al.
Publicado: (2014)

Can inflammatory markers predict response to methotrexate in JIA? Results from the CHARM study
por: Moncrieffe, H, et al.
Publicado: (2011)

Accuracy of preliminary remission criteria some JIA category
por: Fantini, F, et al.
Publicado: (2008)

Mandibular condyle destruction in juvenile idiopathic arthritis (JIA)
por: Zak, M, et al.
Publicado: (2008)

Neuroblastoma versus systemic JIA – a diagnostic dilemma
por: Scalzi, Lisabeth, et al.
Publicado: (2012)

The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
por: Deslypere, G, et al.
Publicado: (2011)

German evidence and consensus based guidelines 2010 for the treatment of juvenile idiopathic arthritis (JIA)
por: Dueckers, G, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4r2ab59h0ng709ac8n1d6mebp5